Gastrointestinal Neoplasm Clinical Trial
Official title:
Primary Tumour Response to Induction Chemotherapy in Synchronously Metastasized Colorectal Cancer
We performed a retrospective data analysis of patients with synchronously metastasized colorectal cancer, comparing the histological response on the primary tumour to chemotherapy combined with either vascular endothelial growth factor (VEGF) or epidermal growth factor receptor (EGFR) inhibition.
We performed a retrospective analysis regarding the response of the primary tumour and the liver metastases of patients with colorectal carcinoma to an induction chemotherapy with antibody therapy, either with a VEGF antibody, or with an EGFR antibody. We investigated 100 Patients with synchronous metastatic colorectal carcinoma, who underwent hepatic resection in Clinic Landstraße or Clinic Favoriten between 2014 and 2021. We investigated the tumour response of the primary tumour, using Rödel score, which is a tumour regression score. We also investigated the tumour response of the liver metastases using Rubbia Brandt tumour regression score. The pathological response was assessed postoperatively in the surgical specimen. In order to ensure a uniform assessment, the pathologists in our HPB center assessed the histological specimens from both treatment locations prior to this analyses. The tumour response of the liver metastases was assessed twice: by radiological tumour assessment via computer tomography (CT) of the abdomen or magnetic resonance imaging (MRI) of the liver with RECIST criteria. Postoperative complications less than 90 days after liver resection were assessed and described according to the classification system by Dindo et al. Day of tumour recurrence and/or death was assessed. We also investigated the difference of recurrence free Survival (RFS) and Overall surcical (OS) between the patients, who received EGFR and the patients, who received VEGF antibody treatment. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Approved for marketing |
NCT00094029 -
A Treatment Protocol for Patients With Gastrointestinal Stromal Tumor (GIST) Who May Derive Benefit From Treatment With SU011248
|
N/A | |
| Not yet recruiting |
NCT06134687 -
Novel Rigidizing Overtube in Colonic Endoscopic Submucosal Dissection
|
N/A | |
| Completed |
NCT01621295 -
Assessing the Patient Experience in Cancer Care
|
N/A | |
| Withdrawn |
NCT03538613 -
Study of People With Metastatic Gastrointestinal Epithelial Cancer Administering Tumor-Infiltrating Lymphocytes in Which the Gene Encoding CISH Was Inactivated Using the CRISPR/Cas9 System
|
Phase 1/Phase 2 | |
| Completed |
NCT02785783 -
Endorings™ Assisted Colonoscopy Versus Standard Colonoscopy for Polyp Detection
|
N/A | |
| Completed |
NCT01129310 -
First Line Study of Irinotecan, Capecitabine and Oxaliplatin in Metastatic Gastric or Gastroesophageal Cancer.
|
Phase 2 | |
| Completed |
NCT03411915 -
A Study of XmAb®18087 in Subjects With NET and GIST
|
Phase 1 | |
| Completed |
NCT00052962 -
Debulking and Chemotherapy With or Without Intraperitoneal Chemotherapy to Treat Peritoneal Carcinomatosis
|
Phase 3 | |
| Recruiting |
NCT06159634 -
Traction vs. No Traction in Colonic ESD
|
N/A | |
| Withdrawn |
NCT00640692 -
Kinase Genotyping of Gastro Intestinal Stomach Tumors (GISTs) From Patients Enrolled in Pfizer A6181112 Phase IIIb Trial
|
||
| Completed |
NCT05320029 -
Disposable Powered Articulating Linear Cutter Stapler in Gastrointestinal Tissue Cutting and Anastomosis
|
N/A | |
| Completed |
NCT00465725 -
A Study Comparing Oral Picoplatin With Intravenous Picoplatin in Subjects With Solid Tumors
|
Phase 1 |